Event Calendar

Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery

PETACH TIKVA, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it will present at the 45th Annual Meeting of the Surgical Infection Society, taking place on May 5-6, 2026, at the Coronado Island Marriott in Coronado, California. The presentation will focus on a detailed analysis of the ASEPSIS (Additional treatment, Serous discharge, Erythema, Purulent exudate, Separation of deep tissues, Isolation of bacteria, and prolonged Stay as inpatient) score data from the Company's Phase 3 SHIELD II trial of D-PLEX₁₀₀.

The presentation will be delivered by Dr. Robert G. Sawyer, MD, FSIS, FACS, FCCM, FIDSA, a Professor and Chair of the Department of Surgery at Western Michigan University Homer Stryker M.D. School of Medicine. Dr. Sawyer also serves as Senior Associate Dean for Research and Editor-in-Chief of the journal Surgical Infections.

The ASEPSIS score is a validated, objective clinical scoring system used to assess the severity of surgical wound infections. It integrates parameters such as wound appearance, antibiotic use, drainage of pus, isolation of pathogenic bacteria, and length of hospital stay. As previously reported in the SHIELD II topline results, treatment with D-PLEX₁₀₀ together with the standard of care resulted in a 64% relative risk reduction (p=0.0103) in the proportion of patients with an ASEPSIS score greater than 20, the threshold indicative of clinically significant wound infection, compared to the standard of care alone.

"The ASEPSIS score outcomes demonstrate not only that D-PLEX₁₀₀ reduces surgical site infections (“SSI”) events by 60%, but also that those infections that ultimately breakthrough are less severe and less complicated," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Fewer SSIs, together with fewer high-severity wound infections, translate directly into better outcomes for patients, including fewer wound complications, less reliance on intravenous antibiotics for treatment of infection, and the potential for earlier hospital discharge. Just as importantly, this carries meaningful implications for hospital economics, with reductions in physician and nursing time, antibiotic stewardship resources, and the overall cost burden associated with extended length of stay and management of complicated postoperative infections.”

Surgical Infection Society 2026 Annual Meeting Presentation Details